BCA
CYTK icon

Berman Capital Advisors’s Cytokinetics CYTK Stock Holding History

Berman Capital Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1K Buy
+48
New +$1.41K ﹤0.01% 1841

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Berman Capital Advisors's CYTK Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Cytokinetics (CYTK) in Q3 2021: 48 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1841 among its holdings.

211 funds tracked by Wall St. Rank hold CYTK as of Q3 2021.

  • Berman Capital Advisors held 48 shares of Cytokinetics worth $1K as of Q3 2021.
  • Cytokinetics was a new Berman Capital Advisors position in Q3 2021.
  • Cytokinetics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1841 holding.
  • 211 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.